Advertisement

Topics

Latest "Indiana Blood Marrow Transplantation" News Stories

15:11 EDT 17th July 2018 | BioPortfolio

Here are the most relevant search results for "Indiana Blood Marrow Transplantation" found in our extensive news archives from over 250 global news sources.

More Information about Indiana Blood Marrow Transplantation on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Indiana Blood Marrow Transplantation for you to read. Along with our medical data and news we also list Indiana Blood Marrow Transplantation Clinical Trials, which are updated daily. BioPortfolio also has a large database of Indiana Blood Marrow Transplantation Companies for you to search.

Showing "Indiana Blood Marrow Transplantation" News Articles 1–25 of 5,500+

Extremely Relevant

Release of the first textbook on blood and marrow transplantation for nurses

(European Society for Blood and Marrow Transplantation) This is the first book specifically written by and for nurses with an interest in Hematopoietic Stem Cell Transplantation (HSCT). It offers the State-of-the-art of transplant nursing and collects knowledge of nursing leaders in the field of HSCT and nursing care.


Blood or marrow transplantation survivors have higher risk of cognitive impairment

Allogeneic blood or marrow transplantation recipients are at a significantly higher risk of cognitive impairment in the years post-transplantation, according to a study published in Journal of Clinical Oncology.

Late mortality after allogeneic blood or marrow transplantation in childhood for leukemia: a report from the Blood or Marrow Transplant Survivor Study-2


Survivors of blood or marrow transplantation are likely to experience cognitive impairment

Allogeneic blood or marrow transplantation recipients are at a significantly higher risk of cognitive impairment in the years post-transplantation, according to a new study. The research helps add a missing piece to a long-unsolved puzzle about post-transplant effects on recipients, specifically that vulnerable subpopulations of similar transplants can benefit from targeted interventions in the ye...

Recommendations from the European Society for Blood and Marrow Transplantation (EBMT) for a curriculum in hematopoietic cell transplantation

New educational app helps support GvHD diagnosis and scoring after HCT

(European Society for Blood and Marrow Transplantation) A new e-Health educational App is now available to assist healthcare professionals in their assessment of graft-versus-host disease (GvHD), a potentially lethal complication of allogeneic stem cell transplantation. Its added value in the identification and accurate evaluation of this disease will be discussed during the 44th Annual Meeting of...

Release of the 7th edition of the International Standards on Hematopoietic Cell Therapy

(European Society for Blood and Marrow Transplantation) The Standards are among the only sets of professional They are produced by international experts from cellular therapy programs.The Standards address every aspect of cell collection, processing and administration that impacts on the quality of products and therapeutic care.* The Standards are considered the 'gold standard' for bone marrow tr...

[News] Source of stem cells in haploidentical transplantation

The use of peripheral blood stem cells (PBSCs) as the stem cell source in patients with acute leukaemia undergoing haploidentical transplantation with post-transplantation cyclophosphamide does not change survival outcomes but significantly increases the risk of acute graft-versus-host disease (GVHD) compared with transplantation using bone marrow, according to recent research.

Researchers engineer human bone marrow tissue

Every day in the bone marrow several billion blood cells are formed. This constant supply is ensured by blood stem cells located in special niches within the marrow. These stem cells can multiply and mature into red and white blood cells, which then leave the bone marrow and enter the bloodstream. F...

AlloHSCT for inv(3)(q21;q26)/t(3;3)(q21;q26) AML: a report from the acute leukemia working party of the European society for blood and marrow transplantation

Elsalys Biotech : LEUKOTAC at the 44th congress of the European Society for Blood and Marrow Transplantation (EBMT)

LEUKOTAC® at the 44th congress of the European Society for Blood and Marrow Transplantation (EBMT) A poster summarising the safety profile results of the randomised Phase 3 testing LEUKOTAC® in patients with steroid-resistant acute graft-versus-host disease (SR-aGvHD) to be presented at the EBMT 2018 ELSALYS BIOTECH to organise a dedicated workshop on LEUKOTAC® with French transpla...

Atara Biotherapeutics to Present at the 44th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)

Post-transplant lymphoproliferative disorder (PTLD) following allogeneic hematopoietic cell transplant (HCT) is an aggressive disease impacting a young population and carrying a significant mortality rate in a relatively short time from diagnosis SOUTH SAN FRANCISCO, Calif., March 16, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunoth...

Cidara Therapeutics to Present Rezafungin Data at the European Society for Blood and Marrow Transplantation 2018 Meeting

SAN DIEGO, March 08, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that two rezafungin abstracts have been accepted for presentation at the 44th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) to be held in Lisbon, Portugal, March 18-21, 20...

SELLAS Life Sciences’ Phase 2 Results for Galinpepimut-S in High-Risk Multiple Myeloma Presented at European Society for Blood and Marrow Transplantation Meeting

- Galinpepimut-S (GPS) induced immune activation against Wilms tumor-1 (WT1) antigen as well as multifunctional cross-epitope T-cell reactivity in patients with aggressive multiple myeloma - Correlation noted between clinical and immune responses with promising progression free survival benefit NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) (“S...

When to immunise if blood stem cells are being transplanted?

After undergoing bone marrow or peripheral blood stem cell transplantation, patients experience a loss of vaccine protection. In a project funded by the Austrian Science Fund FWF, the physician Christina Forstner is investigating how such patients respond to TBE vaccination and at what point this sh...

Fortress Biotech Announces Publication of Phase 1 Data on CNDO-109-Activated Allogeneic Natural Killer Cells in Acute Myeloid Leukemia in Biology of Blood and Marrow Transplantation

NEW YORK, June 19, 2018 (GLOBE NEWSWIRE) -- Fortress Biotech (NASDAQ:FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that data from a Phase 1 clinical trial evaluating Fortress’ CNDO-109-activated allogeneic natural killer (NK) cells in acute myeloid leukemia (AML) patie...

Rogue tweet nearly triples HemoGenyx stock price

HemoGenyx Pharmaceuticals, a bone marrow and blood stem cell transplantation specialist based in the…

BMT Tandem Meetings on Blood & Marrow Transplantation and Cellular Therapy to be Held in Salt Lake City

The BMT Tandem Meetings of the CIBMTR and the ASBMT will take place Feb. 21-25, 2018 at the Salt Palace Convention Center in Salt Lake City, Utah. SALT LAKE CITY (PRWEB) January 23, 2018 The BMT Tandem Meetings of the Center for International Blood & Marrow Transplant Research (CIBMTR) and the American Society for Blood and Marrow Transplantation (ASBMT) will take place Feb. 21-25, 2018 at th...

Research identifies link between rare gene variants and survival after blood and marrow transplant

Blood and marrow transplant, or BMT, is a lifesaving and effective treatment for many patients, but the procedure can cause serious and life-threatening complications.

Relevant

SELLAS Life Sciences Group to Present Complete Phase 2 Correlative Results for its Lead Cancer Immunotherapy Candidate, galinpepimut-S (GPS), in Treatment of Multiple Myeloma: Oral Presentation at the 2018 European Society for Blood and Marrow Transplant

NEW YORK, Jan. 24, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq:SLS) (SELLAS) today announced that an abstract highlighting the detailed description of antigen-specific immune responses and correlation thereof with clinical effects over time has been accepted for oral presentation at the 2018 European Society for Blood and Marrow Transplantation (EBMT) 44th Annual Meet...

Hemogenyx Collaboration with Major US Biotech

Hemogenyx Pharmaceuticals , a biotech developing novel therapies to transform bone marrow, or blood stem cell, transplantation for the treatment of blood diseases, has entered into a collaboration with major U.S. biotechnology company in a deal worth up to approximately $250,000 for Hemogenyx, the company said. The collaboration follows on from the announcement made by the company recently, which ...

A new vulnerability in targeting blood cancer

AML is not a single disease. It is a group of leukemias that develop in the bone marrow from progenitors of specialized blood cells, the so-called myeloid cells. Rapidly growing and dividing, these aberrant cells crowd the bone marrow and bloodstream,...

Gamida Cell to Present Immune Reconstitution Data for its NiCord® Program at the 2018 EBMT Annual Meeting

– NiCord recipients demonstrated rapid and robust immune reconstitution following transplantation – Gamida Cell, a leading cellular and immune therapeutics company, today announced that new data on immune reconstitution (IR) from its phase I/II study of NiCord in high-risk hematologic malignancies will be presented during the 44th Annual Mee...

Vascugen licenses tech for blood vessel regeneration developed at IU School of Medicine

(Indiana University) Vascugen Inc. today announced that it has licensed a suite of intellectual property developed at the Indiana University School of Medicine related to blood vessel formation from adult stem cells. The regenerative medicine company is focused on finding therapies to repair tissues damaged by reduced blood flow due to disease or injury.

Introducing Prof. Shaun McCann, Bone Marrow Transplantation’s New Sommelier


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks